Elie Fahed, MD, provides an overview of what multiple myeloma is, and Beth walks us through her frustrating journey to initial diagnosis as an atypical patient.
Cristina Gasparetto, MD, gives a brief overview of the multiple myeloma disease state and introduces us to Donna, one of her patients diagnosed with multiple myeloma.
The key findings from a phase 3 Spanish study are three-fold: less aggressive initial (induction) therapy with once-weekly—rather than twice-weekly—Velcade (bortezomib) was effective; melphalan outdid thalidomide as a partner to Velcade; and following induction with maintenance therapy may be the best approach for treating multiple myeloma patients over 65 who haven’t received previous treatment.
Updates from the American Society of Hematology meeting and the San Antonio Breast Cancer Symposium.
Monitoring and managing effects of transplantation can be a waiting game.
Advances in stem cell transplantation leads to a changing landscape in treating blood cancers, such as lymphoma, leukemia, and multiple myeloma.
FDA approves Mozobil for non-Hodgkin lymphoma and myeloma, and Degarelix for advanced prostate cancer.
Velcade is now available for newly diagnosed multiple myeloma patients and new drugs emerge as potential treatment to a serious side effect.
News updates from the American Society of Hematology and the San Antonio Breast Cancer Symposium.
The old and the new in myeloma therapy give patients more options.
Satraplatin's approval review deadline gets pushed back by the FDA and a large clinical trial shows Vidaza extends survival in patients with MDS.
Brian Durie, MD, and Susan Novis, president of the International Myeloma Foundation, answer questions about the progress in multiple myeloma.
Updates from the American Society of Hematology Meeting and the San Antonio Breast Cancer Symposium.
Drugs for multiple myeloma and CML reach patients.
